Chime Financial, Inc.'s IPO was met with huge enthusiasm, surging 50% on debut, but the $11.6B+ valuation is aggressive for a barely profitable fintech. Chime excels in targeting underserved Americans ...
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks.
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks.
Corporate insiders will soon be able to unload shares, which could cause some selling pressure but also ultimately reduce volatility by increasing the stock's public float Corporate insiders at ...
Zacks Investment Research on MSN
LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?
LENZ Therapeutics, Inc. (LENZ) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback